CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
胶质母细胞瘤免疫治疗：当前方法与未来展望
英文原题：Immunotherapy in Glioblastoma: Current Approaches and Future Perspectives.
查看英文原题
Immunotherapy in Glioblastoma: Current Approaches and Future Perspectives.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
胶质母细胞瘤（GBM）是最常见的恶性脑肿瘤。尽管采用手术切除、放疗、化疗和肿瘤电场治疗等多模式方案，疾病仍必然复发；观察到的中位生存期仅8个月，5年总生存率仅7%。免疫治疗旨在诱导肿瘤特异性免疫应答，以选择性清除肿瘤细胞。GBM治疗中研究过多种免疫疗法，包括检查点抑制剂、嵌合抗原受体（CAR）T细胞疗法、疫苗疗法、病毒载体疗法和细胞因子疗法。迄今尚无重大突破，免疫治疗广泛应用于GBM仍难以实现，但多项研究正在开展。本文综述GBM免疫治疗方法，重点关注分子信息指导的治疗策略。
展开英文摘要原文
Glioblastoma (GBM) is the most common malignant brain tumor. Despite multimodality treatment with surgical resection, radiation therapy, chemotherapy, and tumor treating fields, recurrence is universal, median observed survival is low at 8 months and 5-year overall survival is poor at 7%. Immunotherapy aims to generate a tumor-specific immune response to selectively eliminate tumor cells.
In treatment of GBM, immunotherapy approaches including use of checkpoint inhibitors, chimeric antigen receptor (CAR) T-Cell therapy, vaccine-based approaches, viral vector therapies, and cytokine-based treatment has been studied. While there have been no major breakthroughs to date and broad implementation of immunotherapy for GBM remains elusive, multiple studies are underway. In this review, we discuss immunotherapy approaches to GBM with an emphasis on molecularly informed approaches.
论文信息
- 作者
- Sener U、Ruff MW、Campian JL
- 第一作者单位
- Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA.United States
- 通讯作者单位
- Department of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA.United States
- 文献类型
- 综述
- 期刊
- International journal of molecular sciences2022 Jun 24
- 原文标识
- PubMed 35806051 · DOI 10.3390/ijms23137046
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →